Guidance For Industry General Considerations For The Clinical Evaluation Of Drugs
Download Guidance For Industry General Considerations For The Clinical Evaluation Of Drugs full books in PDF, epub, and Kindle. Read online free Guidance For Industry General Considerations For The Clinical Evaluation Of Drugs ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads.
Author |
: United States. Food and Drug Administration. Bureau of Drugs |
Publisher |
: |
Total Pages |
: 20 |
Release |
: 1977 |
ISBN-10 |
: STANFORD:24501026232 |
ISBN-13 |
: |
Rating |
: 4/5 (32 Downloads) |
Synopsis General considerations for the clinical evaluation of drugs by : United States. Food and Drug Administration. Bureau of Drugs
Author |
: United States. Food and Drug Administration |
Publisher |
: |
Total Pages |
: 20 |
Release |
: 1977 |
ISBN-10 |
: MINN:31951003051226S |
ISBN-13 |
: |
Rating |
: 4/5 (6S Downloads) |
Synopsis General Considerations for the Clinical Evaluation of Drugs by : United States. Food and Drug Administration
Author |
: United States. Food and Drug Administration. Bureau of Drugs |
Publisher |
: |
Total Pages |
: 28 |
Release |
: 1977 |
ISBN-10 |
: UOM:39015003205070 |
ISBN-13 |
: |
Rating |
: 4/5 (70 Downloads) |
Synopsis General Considerations for the Clinical Evaluation of Drugs in Infants and Children by : United States. Food and Drug Administration. Bureau of Drugs
Author |
: |
Publisher |
: |
Total Pages |
: |
Release |
: 1990 |
ISBN-10 |
: OCLC:934369409 |
ISBN-13 |
: |
Rating |
: 4/5 (09 Downloads) |
Synopsis Guidance for Industry - General Considerations for the Clinical Evaluation of Drugs by :
Author |
: United States. Food and Drug Administration |
Publisher |
: |
Total Pages |
: 28 |
Release |
: 1977 |
ISBN-10 |
: MINN:31951003051182M |
ISBN-13 |
: |
Rating |
: 4/5 (2M Downloads) |
Synopsis General Considerations for the Clinical Evaluation of Drugs in Infants and Children by : United States. Food and Drug Administration
Author |
: |
Publisher |
: |
Total Pages |
: |
Release |
: 1977 |
ISBN-10 |
: OCLC:251709471 |
ISBN-13 |
: |
Rating |
: 4/5 (71 Downloads) |
Synopsis General Considerations for the Clinical Evaluation of Drugs in Infants and Children by :
Author |
: United States. Food and Drug Administration. Bureau of Drugs |
Publisher |
: |
Total Pages |
: 20 |
Release |
: 1977 |
ISBN-10 |
: UOM:39015003205054 |
ISBN-13 |
: |
Rating |
: 4/5 (54 Downloads) |
Synopsis General Considerations for the Clinical Evaluation of Drugs by : United States. Food and Drug Administration. Bureau of Drugs
Author |
: Ruth R. Faden |
Publisher |
: National Academies |
Total Pages |
: 44 |
Release |
: 1994-01-15 |
ISBN-10 |
: NAP:13495 |
ISBN-13 |
: |
Rating |
: 4/5 (95 Downloads) |
Synopsis Women and Health Research by : Ruth R. Faden
Examines the facts on women's participation as subjects in medical research and explores issues related to maintaining justice in clinical studies. Experts in ethics, research, medicine and industry present general principles for the ethical conduct of research on women while highlighting the limitations of science, legal liabilities, and relevant governmental policies. Offers an historical overview treating topics such as thalidomide and DES research. Annotation c. by Book News, Inc., Portland, Or.
Author |
: |
Publisher |
: |
Total Pages |
: |
Release |
: 1977 |
ISBN-10 |
: OCLC:256103569 |
ISBN-13 |
: |
Rating |
: 4/5 (69 Downloads) |
Synopsis General Considerations for the Clinical Evaluation of Drugs by :
Author |
: National Research Council |
Publisher |
: National Academies Press |
Total Pages |
: 163 |
Release |
: 2010-12-21 |
ISBN-10 |
: 9780309186513 |
ISBN-13 |
: 030918651X |
Rating |
: 4/5 (13 Downloads) |
Synopsis The Prevention and Treatment of Missing Data in Clinical Trials by : National Research Council
Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies often lack a substantial percentage of data. This missing data reduces the benefit provided by the randomization and introduces potential biases in the comparison of the treatment groups. Missing data can arise for a variety of reasons, including the inability or unwillingness of participants to meet appointments for evaluation. And in some studies, some or all of data collection ceases when participants discontinue study treatment. Existing guidelines for the design and conduct of clinical trials, and the analysis of the resulting data, provide only limited advice on how to handle missing data. Thus, approaches to the analysis of data with an appreciable amount of missing values tend to be ad hoc and variable. The Prevention and Treatment of Missing Data in Clinical Trials concludes that a more principled approach to design and analysis in the presence of missing data is both needed and possible. Such an approach needs to focus on two critical elements: (1) careful design and conduct to limit the amount and impact of missing data and (2) analysis that makes full use of information on all randomized participants and is based on careful attention to the assumptions about the nature of the missing data underlying estimates of treatment effects. In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data.